retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Targeting GLP-1, & GCG in and Type Diabetes Research Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Pay in 4 interest-free payments of $7.41 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
























